Evidence map›Paper›PMID 29104721›Full record

ReviewThe Journal of clinical and aesthetic dermatology2017

Topical a-Agonist Therapy for Persistent Facial Erythema of Rosacea and the Addition of Oxmetazoline to the Treatment Armamentarium: Where Are We Now?

James Q Del Rosso

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in The Journal of clinical and aesthetic dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS).The Journal of clinical and aesthetic dermatology · 2020
    Article
  6. Review
  7. Article
  8. Article
  9. Conventional and Novel Treatment Modalities in Rosacea.Clinical, cosmetic and investigational dermatology · 2020
    Review
  10. Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS).The Journal of clinical and aesthetic dermatology · 2019
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

James Q Del RossoDr. Del Rosso is Research Director at JDR Dermatology Research, Las Vegas, Nevada and at Henderson Dermatology Research in Henderson, Nevada; is Adjunct Clinical Professor (Dermatology) at Touro University Nevada, Las Vegas, Nevada; and practices Dermatology and Cutaneous Surgery at Thomas Dermatology in Las Vegas, Nevada.
Touro University Nevada · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of vasoactivity in rosacea-affected skin led to the development of two topical α-adrenergic receptor agonists, brimonidine tartrate 0.5% gel and oxymetazoline hydrochloride 1% cream, both approved by the United States Food and Drug Administration for treatment of persistent facial erythema of rosacea. In this article, the author discusses challenges related to the treatment of persistent facial erythema of rosacea and the use of a-agonist therapy. The author also discusses cases of worsening of facial erythema after the application of brimonidine, as well as briefly reviews recently reported clinical data on oxymetazoline. Finally, the author attempts to differentiate some potential mechanistic differences between these two agents.

Indexed as

facial erythemaflushingparadoxical erythemareboundrosaceavasoactivityα-agonist therapy

Identifiers

PMID29104721
PMCPMC5605221
OpenAlexW3021393195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.